Stock News

TherapeuticsMD (AMEX:TXMD) Stock “Buy” Rating Maintained at Oppenheimer; The Target is Set to $10.0; Select Medical Holdings (SEM) Sentiment Is 1.27

Select Medical Holdings Corporation, through its subsidiary, Select Medical Corporation, operates specialty hospitals, outpatient rehabilitation clinics, and occupational medicine centers in the United States. The company has market cap of $2.23 billion. The companyÂ’s Specialty Hospitals segment operates long term acute care hospitals and inpatient acute rehabilitative hospitals. It has a 23.12 P/E ratio. This segment offers various medical services for the treatment of respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders, and cancer.

Among 10 analysts covering TherapeuticsMD (AMEX:TXMD), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. TherapeuticsMD has $34 highest and $6 lowest target. $14.38’s average target is 166.79% above currents $5.39 stock price. TherapeuticsMD had 37 analyst reports since April 4, 2016 according to SRatingsIntel. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) earned “Buy” rating by Cantor Fitzgerald on Monday, July 17. The rating was maintained by Oppenheimer on Tuesday, August 29 with “Buy”. The stock of TherapeuticsMD, Inc. (NASDAQ:TXMD) has “Buy” rating given on Friday, December 29 by Noble Financial. Cantor Fitzgerald maintained TherapeuticsMD, Inc. (NASDAQ:TXMD) rating on Thursday, August 10. Cantor Fitzgerald has “Buy” rating and $3300 target. On Thursday, September 14 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained TherapeuticsMD, Inc. (NASDAQ:TXMD) rating on Wednesday, August 16. Cantor Fitzgerald has “Buy” rating and $33.0 target. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, December 19. The firm earned “Buy” rating on Sunday, January 28 by Oppenheimer. The firm has “Buy” rating given on Monday, November 6 by Oppenheimer. The stock has “Buy” rating by Cantor Fitzgerald on Monday, September 4.

TherapeuticsMD, Inc. operates as a womenÂ’s health care product company. The company has market cap of $1.17 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

The stock increased 1.51% or $0.08 during the last trading session, reaching $5.39. About 1.94 million shares traded. TherapeuticsMD, Inc. (AMEX:TXMD) has declined 46.30% since February 21, 2017 and is downtrending. It has underperformed by 63.00% the S&P500.

Investors sentiment increased to 1.73 in Q3 2017. Its up 0.69, from 1.04 in 2017Q2. It increased, as 9 investors sold TherapeuticsMD, Inc. shares while 28 reduced holdings. 24 funds opened positions while 40 raised stakes. 162.04 million shares or 5.51% more from 153.57 million shares in 2017Q2 were reported. Royal State Bank Of Canada reported 29,802 shares. 1492 Cap Mgmt stated it has 390,702 shares or 1.83% of all its holdings. Vanguard Gru reported 10.91 million shares or 0% of all its holdings. Northern reported 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Alyeska Inv Gp Limited Partnership invested in 531,610 shares or 0.02% of the stock. Raymond James Na has 10,000 shares. Rhumbline Advisers stated it has 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). Ing Groep Nv accumulated 267,962 shares. Susquehanna Intll Group Limited Liability Partnership invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Sg Americas Secs Limited Liability Company holds 105,069 shares. Proshare Ltd Limited Liability Company owns 10,729 shares or 0% of their US portfolio. Raymond James And Assoc accumulated 389,563 shares or 0% of the stock. 35,800 are held by Quantbot Technologies Lp. Amalgamated National Bank & Trust reported 0% stake. Td Asset invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD).

North Tide Capital Llc holds 18.43% of its portfolio in Select Medical Holdings Corporation for 4.50 million shares. Smith Graham & Co. Investment Advisors Lp owns 671,617 shares or 1.35% of their US portfolio. Moreover, Hood River Capital Management Llc has 1.26% invested in the company for 1.03 million shares. The New York-based Brigade Capital Management Lp has invested 1.25% in the stock. Deerfield Management Co, a New York-based fund reported 1.19 million shares.

The stock increased 0.30% or $0.05 during the last trading session, reaching $16.65. About 212,938 shares traded. Select Medical Holdings Corporation (SEM) has risen 12.50% since February 21, 2017 and is uptrending. It has underperformed by 4.20% the S&P500.

Analysts await Select Medical Holdings Corporation (NYSE:SEM) to report earnings on February, 22 after the close. They expect $0.19 earnings per share, up 58.33% or $0.07 from last year’s $0.12 per share. SEM’s profit will be $25.42M for 21.91 P/E if the $0.19 EPS becomes a reality. After $0.14 actual earnings per share reported by Select Medical Holdings Corporation for the previous quarter, Wall Street now forecasts 35.71% EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *